PMV Pharma was co-founded by Dr. Arnold Levine, one of the discoverers of the p53 protein and a professor emeritus at the Simons Center for Systems Biology at the Institute for Advanced Study. p53 is the most commonly mutated gene in cancer, with over 50 percent of all human tumors containing a p53 mutant protein. PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/02/14 | $30,000,000 | Series A |
InterWest Partners OrbiMed Advisors Osage University Partners | undisclosed |
| 02/27/17 | $74,000,000 | Series B |
InterWest Partners OrbiMed Advisors Osage University Partners Topspin Partners  | undisclosed |
| 08/04/20 | $70,000,000 | Series D |
Avoro Capital Advisors Boxer Capital Nextech Invest OrbiMed Advisors RA Capital Management Viking Global Investors Wellington Management Company | undisclosed |
